主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRLD
#2987
Prelude Therapeutics Incorporated
2.7
6
-5.80%
版块:
基础:
利润货币:
日范围
年范围
日变化
-5.80%
每月变动
+28.37%
6个月变化
+113.95%
年变化
+253.85%
前一天收盘价
2.9
3
Open
2.7
6
Bid
Ask
Low
2.7
6
High
2.7
6
交易量
3
市场
股票
医疗保健
PRLD
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
42.18 M
42.3 M
43.6 M
43.74 M
43.75 M
173.4 M
Valuation ratios
Enterprise value
102.79 M
57.85 M
3.09 M
20.06 M
42.99 M
124 M
Price to earnings ratio
-1.18
-0.76
-0.46
-0.5
-0.99
-2.7
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-1.4
-0.94
-0.55
-0.57
-1.09
-3.15
Price to book ratio
0.19
0.74
0.1
0.13
0.3
1.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.16
0.16
0.23
0.27
0.21
0.87
Return on equity %
0.21
0.22
0.31
0.41
0.34
1.28
Return on invested capital %
—
—
—
—
—
—
Gross margin %
100
—
—
—
100
—
Operating margin %
1 145.87
—
—
—
314.12
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 075.7
—
—
—
303.46
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
7.04
5.3
5.18
3.68
3.21
17.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
—
—
—
0.06
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.36
0.27
0.45
0.34
0.25
1.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
2.03
1.76
1.3
0.96
0.72
4.75
Net current asset value per share
2.06
1.79
1.35
1.01
0.77
4.92
Tangible book value per share
2.06
1.73
1.36
1
0.77
4.86
Working capital per share
1.77
1.45
1.09
0.74
0.53
3.81
Book value per share
2.06
1.73
1.36
1
0.77
4.86
新闻
Prelude Therapeutics股票获Citizens重申"市场表现优于大盘"评级
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
Prelude Therapeutics股价在FDA批准癌症药物IND申请后飙升
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
Citizens重申Prelude Therapeutics股票评级为"市场表现优于大盘"
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
英科达股价创52周新高,达108.81美元
Prelude Therapeutics 2025年第三季度财报电话会议记录:股价保持稳定
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness